慢性阻塞性肺疾病发生及治疗反应差异相关基因的研究进展

doi:10.20047/j.issn1673-7210.2023.28.10

摘要
图/表
参考文献(37)
相关文章 (15)

全文: PDF (616 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要慢性阻塞性肺疾病（COPD）是一种遗传和环境等多种因素共同作用所致的肺部疾病，以不可逆的气流受限为主要特征。近年来，COPD遗传学相关研究又有了一些新的发现，如丝氨酸蛋白酶抑制剂A1基因的rs8004738位点、转化生长因子β1基因的rs1982073位点、非受体型蛋白酪氨酸磷酸酶6基因、端粒酶逆转录酶基因及基质金属蛋白酶基因家族均与COPD显著相关；在此基础上还发现了多个与COPD治疗反应差异有关的基因，如钾内向整流通道J亚家族成员2基因，皮质类固醇受体基因及糖皮质激素诱导转录因子１基因。这些新发现的基因及位点多态性为COPD的发病机制提供了新见解，为寻找COPD诊疗新靶点，建立COPD患者不同表型的分型依据及预测模型提供了方向，推动了个体化治疗的发展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	董晗1　　欧静1　　张程2　　张湘燕2

关键词 ：慢性阻塞性肺疾病, 基因测序, 易感基因, 治疗反应差异

Abstract：Chronic obstructive pulmonary disease (COPD) is a lung disease caused by a combination of genetic and environmental factors, and is characterized by irreversible airflow limitations. In recent years, new discoveries have been made in COPD genetics-related studies, such as the rs8004738 locus of serpin family A member 1, the rs1982073 locus of transforming growth factor β1, protein tyrosine phosphatase non-receptor type 6, telomerase reverse tranasecriptase gene, and matrix metalloproteinases have all been significantly associated with COPD; on this basis, several genes associated with differences in treatment response of COPD were also identified, such as potassium inwardly rectifying channel subfamily J member 2, nuclear receptor subfamily 3 group C member 1, and glucocorticoid inducible transcription factor 1. These newly identified genes and loci provide new insights into the pathogenesis of COPD, provide directions for finding new targets for the diagnosis and treatment of COPD, establish the basis for typing and prediction models for different phenotypes of COPD patients and promote the development of individualized therapy.

Key words： Chronic obstructive pulmonary disease Gene sequencing Susceptibility genes Differences in treatment response

基金资助:中国医学科学院中央级公益性科研院所基本科研业务费项目（2019PT320003）；
贵州省科技计划项目（黔科合基础-ZK〔2021〕一般350）。

通讯作者: 张湘燕（1962.3-），女，硕士，二级教授，主任医师，博士生导师，贵州省人民医院党委书记，主要从事慢性阻塞性肺疾病临床方面的研究。

作者简介: 董晗（1997.2-），女，遵义医科大学附属贵州省人民医院2020级内科学专业在读硕士研究生，主要从事呼吸系统疾病临床方面的研究。

引用本文:

董晗1　　欧静1　　张程2　　张湘燕2. 慢性阻塞性肺疾病发生及治疗反应差异相关基因的研究进展[J]. 中国医药导报, 2023, 20(28): 49-53.
DONG Han1 OU Jing1 ZHANG Cheng2 ZHANG Xiangyan2. Research progress on genes related to occurrence and differences in treatment response of chronic obstructive pulmonary disease. 中国医药导报, 2023, 20(28): 49-53.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.28.10 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I28/49

[1] Global strategy for the diagnosis，management and prevention of chronic obstructive pulmonary disease （2022 report）[R/OL]. https： //goldcopd.org/.
[2] Neumeier A，Keith R. Clinical Guideline Highlights for the Hospitalist：The GOLD and NICE Guidelines for the Management of COPD [J]. J Hosp Med，2020，15（4）：240-241.
[3] Labaki WW，Rosenberg SR. Chronic Obstructive Pulmonary Disease [J]. Ann Intern Med，2020，173（3）：17-32.
[4] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global，regional，and national incidence，prevalence，and years lived with disability for 354 diseases and injuries for 195 countries and territories，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet，2019，393（10190）：e44.
[5] Silverman EK，Chapman HA，Drazen JM，et al. Genetic Epidemiology of Severe，Early-Onset Chronic Obstructive Pulmonary Disease [J]. Am J Respir Crit Care Med，1998，157（6）：1770-1778.
[6] Christenson SA，Smith BM，Bafadhel M，et al. Chronic obstructive pulmonary disease [J]. Lancet，2022，399（10342）：2227-2242.
[7] Agustí A，Melén E，DeMeo DL，et al. Pathogenesis of chronic obstructive pulmonary disease：understanding the contributions of gene-environment interactions across the lifespan [J]. Lancet Respir Med，2022，10（5）：512-524.
[8] Brown DG，Wobst HJ. A Decade of FDA-Approved Drugs （2010-2019）：Trends and Future Directions [J]. J Med Chem， 2021，64（5）：2312-2338.
[9] Ghosh AJ，Hobbs BD. Recent advancements in understanding the genetic involvement of alpha-1 antitrypsin deficiency associated lung disease：a look at future precision medicine approaches [J]. Expert Rev Respir Med，2022，16（2）：173- 182.
[10] Foil KE. Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency [J]. Ther Adv Chronic Dis，2021，12_suppl：20406223211015954.
[11] Sangeetha T，Nargis BT，Balamuralikrishnan B，et al. Influence of SERPINA1 Gene Polymorphisms on Anemia and Chronic Obstructive Pulmonary Disease [J]. J Renin Angiot- ensin Aldosterone Syst，2022，2022：2238320.
[12] 邓笑伟，袁存花，常德.SERPINA1基因多态性及吸烟与慢性阻塞性肺疾病易感性关系的研究[J].中华结核和呼吸杂志，2018，41（5）：322.
[13] Wang J，Xiang H，Lu Y，et al. Role and clinical significance of TGF β1 and TGF βR1 in malignant tumors [J]. Int J Mol Med，2021，47（4）：55.
[14] Liao N，Zhao H，Chen ML，et al. Association between the TGF-β1 polymorphisms and chronic obstructive pulmonary disease：a meta-analysis [J]. Biosci Rep，2017，37（4）：BSR 20170747.
[15] Kiratikanon S，Chattipakorn SC，Chattipakorn N，et al. The regulatory effects of PTPN6 on inflammatory process：Reports from mice to men [J]. Arch Biochem Biophys，2022， 721：109189.
[16] Sharma Y，Bashir S，Bhardwaj P，et al. Protein Tyrosine Phosphatase SHP-1：Resurgence as New Drug Target for Human Autoimmune Disorders [J]. Immunol Res，2016，64（4）：804-819.
[17] Bossé Y，Lamontagne M，Gaudreault N，et al. Early-Onset Emphysema in a Large French-Canadian Family：A Genetic Investigation [J]. Lancet Respir Med，2019，7（5）：427-436.
[18] Dratwa M，Wysoczańska B，?覵acina P，et al. TERT-Regulation and Roles in Cancer Formation[J]. Front Immunol，2020，11：589929.
[19] Stanley SE，Chen JJL，Podlevsky JD，et al. Telomerase Mutations in Smokers with Severe Emphysema [J]. J Clin Invest，2014，125（2）：563-570.
[20] Ding Y，Li Q，Wu C，et al. TERT gene polymorphisms are associated with chronic obstructive pulmonary disease risk in the Chinese Li population [J]. Mol Genet Genomic Med，2019，7（8）：e773.
[21] Bassiouni W，Ali MAM，Schulz R. Multifunctional intracellular matrix metalloproteinases：implications in disease [J]. FEBS J，2021，288（24）：7162-7182.
[22] Christopoulou ME，Papakonstantinou E，Stolz D. Matrix Metalloproteinases in Chronic Obstructive Pulmonary Disease [J]. Int J Mol Sci，2023，24（4）：3786.
[23] Jeon S，Kim TK，Jeong SJ，et al. Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis [J]. Circulation，2020，142（18）：1736-1751.
[24] Bormann T，Maus R，Stolper J，et al. Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice [J]. Respir Res，2022，23（1）：180.
[25] Gilowska I，Kasper ?覵，Bogacz K，et al. Impact of Matrix Metalloproteinase 9 on COPD Development in Polish Patients：Genetic Polymorphism，Protein Level，and Their Relationship with Lung Function [J]. Biomed Res Int，2018， 2018：6417415.
[26] Jiang S，Yang ZH，Chen YY，et al. MMP-9 genetic polymorphism may confer susceptibility to COPD [J]. Genet Mol Res，2016，15（2）.
[27] Atkinson JJ，Lutey BA，Suzuki Y，et al. The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema [J]. Am J Respir Crit Care Med，2011，183（7）：876-884.
[28] Gilowska I，Majorczyk E，Kasper ?覵，et al. The role of MMP- 12 gene polymorphism-82 A-to-G（rs2276109）in immun- opathology of COPD in polish patients：a case control study [J]. BMC Med Genet，2019，20（1）：19.
[29] Tacheva T，Dimov D，Aleksandrova E，et al. The G allele of MMP12-82 A＞G promoter polymorphism as a protective factor for COPD in Bulgarian population [J]. Arch Physiol Biochem，2017，123（5）：371-376.
[30] Bchir S，Ben Nasr H，Garrouch A，et al. MMP-3（-1171 5A/6A; Lys45Glu）variants affect serum levels of matrix metalloproteinase（MMP）-3 and correlate with severity of COPD：A study of MMP-3，MMP-7 and MMP-12 in a Tunisian population [J]. J Gene Med，2018，20（1）.
[31] Tashkin DP，Celli B，Decramer M，et al. Bronchodilator Res- ponsiveness in Patients with COPD [J]. Eur Respir J，2008， 31（4）：742-750.
[32] Loth DW，Soler Artigas M，Gharib SA，et al. Genome-wide association analysis identifies six new loci associated with forced vital capacity [J]. Nat Genet，2014，46（7）：669-677.
[33] Hardin M，Cho MH，McDonald ML，et al. A Genome-Wide Analysis of the Response to Inhaled Β2-Agonists in Chronic Obstructive Pulmonary Disease [J]. Pharmacogenomics J，2015，16（4）：326-335.
[34] Obeidat M，Faiz A，Li X，et al. The Pharmacogenomics of Inhaled Corticosteroids and Lung Function Decline in COPD [J]. Eur Respir J，2019，54（6）：1900521.
[35] Rijavec M，■avbi M，Lopert A，et al. GLCCI1 Polymorphism rs37973 and Response to Treatment of Asthma With Inhaled Corticosteroids [J]. J Investig Allergol Clin Immunol，2018，28（3）：165-171.
[36] Tantisira KG，Lasky-Su J，Harada M，et al. Genomewide Association between GLCCI1 and Response to Glucocorticoid Therapy in Asthma [J]. N Engl J Med，2011，365（13）：1173-1183.
[37] Mosteller M，van den Berge M，Hosking L，et al. Genetic evaluation of the effect of GLCCI1 rs37973 on corticosteroid response in chronic obstructive pulmonary disease [J]. COPD Res Prac，2017，3（1）：2.